Stockscreener 앱 받기
0.8541
19.42%
-0.2059
시간 외 거래:
.88
0.0259
+3.03%
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte Announces $20 Million Registered Direct Offering - TipRanks
Humacyte (NASDAQ: HUMA) to raise $20M selling 25M shares at $0.80 - Stock Titan
Humacyte (Nasdaq: HUMA) prices $20M registered direct stock sale - Stock Titan
Humacyte stock price target maintained at $6 by BTIG on Saudi deal - Investing.com Australia
Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today? - MSN
Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today? - Stocktwits
HUMA Drops 19.6%: Sharp Downturn Triggered by $20M Sale Amid Market Turbulence - Bitget
Humacyte Receives Purchase Commitment For Symvess Product In Saudi Arabia - marketscreener.com
Humacyte secures $1.5M Saudi Arabia purchase commitment - Investing.com
Humacyte Ends ATM Program, Highlights Symvess Global Expansion - TipRanks
Saudi hospitals to evaluate Humacyte vessel under $1.475M deal - Stock Titan
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock - Yahoo Finance Singapore
Humacyte (HUMA) halts $60M ATM as Symvess gains early sales and KSA deal - Stock Titan
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Humacyte submits marketing application for Symvess in Israel By Investing.com - Investing.com South Africa
Risk Hedge: What is the long term forecast for Humacyte Inc stockWeekly Investment Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
Humacyte stock rating reiterated at Buy by D. Boral Capital - Investing.com
Humacyte submits marketing application for Symvess in Israel - Investing.com
Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair - Bitget
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair - The Manila Times
Battlefield-tested trauma vessel targets Israeli hospitals next - Stock Titan
Humacyte, Senseonics jump as Barclays issues new Overweight ratings - MSN
Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Market Recap: Whats the fair value of Humacyte Inc Equity Warrant stock2026 Review & Community Driven Trade Alerts - baoquankhu1.vn
Aug Macro: What are Humacyte Inc Equity Warrants technical support levels2026 Risk Factors & Weekly High Momentum Picks - baoquankhu1.vn
Humacyte at Barclays Conference: Strategic Insights and Future Plans By Investing.com - Investing.com Canada
Risk Analysis: Will Humacyte Inc benefit from rising consumer demandQuarterly Trade Summary & Safe Entry Zone Identification - baoquankhu1.vn
Institution Moves: Does Humacyte Inc have a sustainable dividend2026 Action & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Humacyte jumps as US legislation backs bioengineered vessels - MSN
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Humacyte, Inc. (HUMA) Is Viewed Favorably by Analysts: Does This Hold Up? - Bitget
HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Stocktwits
Humacyte at TD Cowen Conference: Strategic Advances in Vascular Care By Investing.com - Investing.com Canada
Bioengineered tissue firm Humacyte lines up back-to-back March investor talks - Stock Titan
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Humacyte, Inc. to Contact the Firm Today! - ACCESS Newswire
US Stocks Recap: Can Humacyte Inc sustain its profitabilityTrend Reversal & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Humacyte To Participate in Upcoming Investor Conferences - Bitget
Levels Update: What is the long term forecast for Humacyte Inc stock2025 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 527% Upside with Innovative Biotech Solutions - DirectorsTalk Interviews
HUMA Should I Buy - Intellectia AI
HUMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP - MarketBeat
Will Humacyte Inc. Equity Warrant face regulatory challengesWeekly Gains Report & Free Community Supported Trade Ideas - mfd.ru
What’s the fair value of Humacyte Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - mfd.ru
Why Humacyte Inc. stock is favored by top institutions2025 Retail Activity & Fast Gaining Stock Strategy Reports - mfd.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unpacking A 570% Potential Upside - DirectorsTalk Interviews
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Insider Trends: Should I invest in Humacyte Inc Equity Warrant before earningsJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting - Bitget
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - The Manila Times
Hedge Fund Moves: Can Humacyte Inc deliver consistent EPS growthTrade Ideas & Accurate Trade Setup Notifications - baoquankhu1.vn
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential - Yahoo Finance
Humacyte Shares Surge on US Defense Funding News - StocksToTrade
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte promotes critical role of vascular health in February - Traders Union
Is Humacyte Inc. backed by strong institutional buyingWeekly Trade Recap & Proven Capital Preservation Methods - mfd.ru
Surprises Report: Whats the fair value of Humacyte Inc stock2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):